TVGN Stock — Tevogen Inc.

Latest documents

what the company just published, in one sentence each

2026

Nov 4

Current report 8-K Events of Nov 2

Director or officer change, or executive pay AI summary on its way

Nov 3

Current report 8-K Events of Oct 27

Debt repaid alongside performance-conditioned CEO stock award

Tevogen Inc. extended its facility to May 31, 2029 and repaid $7.4 million plus $177,880 interest in 1,000,000 Principal Shares and 23,733 Interest Shares. Ryan Saadi received 50,000,000 restricted shares vesting at $1.0 billion revenue by December 31, 2031.

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Director or officer change, or executive pay Read from the first part of this long document

6 source passages

The Amendment, among other things: (i) extends the period during which the Company can request borrowings under the Facility from May 31, 2027 to May 31, 2029; As of the First Amendment Effective Date, the outstanding principal balance of the loans borrowed under the Original Agreement was $7.4 million. Following the Amendment, the Company elected to repay the entire outstanding principal balance, together with $177,880 of accrued and unpaid interest, in shares of Common Stock at the Share Payment Price. On November 2, 2026, the Company issued to the Lender 1,000,000 Principal Shares and 23,733 Interest Shares in payment thereof thereby eliminating all outstanding liabilities under the Agreement. On November 2, 2026 (the “Grant Date”), Tevogen Inc. (the “Company”) granted Ryan Saadi, Chief Executive Officer and Chairperson of the Company’s Board of Directors (the “Board”), a restricted stock award (the “RSA”) under the Tevogen Inc. 2024 Omnibus Incentive Plan (the “Plan”), covering 50,000,000 shares (“Restricted Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”). The Restricted Shares will vest only upon the Board’s certification of the Company’s achievement of $1.0 billion in aggregate revenue by December 31, 2031 (the “Revenue Threshold”) and satisfaction of the other applicable vesting conditions. Open the document at this passage

Sep 30

Current report 8-K Events of Sep 29

Other events

Tevogen Inc. regained Nasdaq Global Market continued-listing compliance after receiving written notice on September 29, 2026 that it met the $50 million minimum market value requirement; both previously disclosed Nasdaq compliance matters are now closed.

Sep 16

Current report 8-K Events of Sep 14

Director or officer change, or executive pay AI summary on its way

Sep 10

Current report 8-K Events of Sep 9

Other events AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$21.61M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+16.3%

Year over year · more shares

Price change (1Y)

—

Trailing year

Short interest

0.9%

Latest settlement · 10.4 days to cover

View all 122 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 16.6 · calm Equity put/call 0.44

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −29%

below

Price vs 50-day avg −17%

below

RSI (14) 38

neutral

MACD trend Negative

52-week position 8%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −12%

trailing

6-month return −16%

trailing

YTD return −65%

this year

Relative strength −18%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $7 › 200d $8 — 200d above 50d

Institutional flow Accumulating

17 of 63 funds reported for Sep 30 · net +15.0K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.85% of shares out · ▼ -0.3% MoM · 10.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

63 holders — mid 3-yr range

Squeeze score 51

elevated · 0–100

Fundamentals

Poor

EPS growth −131%

Y/Y

Free cash flow $-12.4M

Quant / Vol

risk profile

Very High

Volatility 113%

annualized · 1-yr

Max drawdown −87%

past year

ATR 9.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−29% Bearish

Price vs 50-day avg

−17% Bearish

RSI (14)

38 Neutral

MACD trend

Negative Bearish

52-week position

8% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $7 › 200d $8 — 200d above 50d

Institutional flow Accumulating

17 of 63 funds reported for Sep 30 · net +15.0K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.85% of shares out · ▼ -0.3% MoM · 10.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

63 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $4 Now $6 · 8% Range high $28

vs 200-day avg -29% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TVGN Tevogen Inc. this stock	$37.25M	—	—	—	1.6%
VRTX Vertex Pharmaceuticals Inc	$139.20B	+21.1%	+46.2%	35.4	1.7%
REGN Regeneron Pharmaceuticals, Inc.	$98.29B	+20.6%	+20.8%	21.0	2.1%
MRNA Moderna, Inc.	$91.20B	+776.2%	+4.3%	—	8.2%
CSLLY Csl Ltd	$67.38B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

61

% held: 155.8%
Reported: 17 of 63
Top holder: FourWorld Capital Managem…

Held Float

View

Held by Funds

Fund positions

22

View

Short & Settlement

Short Interest Falling

Shares short

55.4K

Days to cover: 10.4d
Change: -169 sh

View

Short Volume

Short vol %

70%

As of: Nov 4, 2026

Short Total

View

Fails to Deliver

FTD shares

47

Value: $367
As of: Sep 23, 2026

View

Off-Exchange

Off-exchange %

41.7%

Week of: Sep 28, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-26.3M

EPS diluted: $-8.08

View

Filings

SEC Filings

Latest

8-K

Filed: Nov 4, 2026
This year: 21

View

Proposed Sales

Value

$103.2K

Shares: 330.0K
Filed: Feb 6, 2026

View

Earnings & Events

Investor Relations

	5D	20D	120D	MTD	YTD
TVGN	-8.3%	-11.9%	-15.5%	-3.1%	-65.4%
SPY	-0.7%	-1.3%	+2.5%	+1.5%	+12.5%
vs SPY	-7.6%	-10.5%	-18.0%	-4.5%	-77.9%

TVGN · Tevogen Inc.

Price & Indicators

Latest documents

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance